A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

NCT02993783 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy of the drug; no safety concern

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Vedolizumab

Sponsor

Millennium Pharmaceuticals, Inc.